CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NYSEMKT:CVM
- CUSIP: N/A
- Web: N/A
- Market Cap: $19.88 million
- Outstanding Shares: 229,827,000
- 50 Day Moving Avg: $0.10
- 200 Day Moving Avg: $0.12
- 52 Week Range: $0.06 - $0.55
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.30
- P/E Growth: 0.0000
- Annual Revenue: $265,736.00
- Price / Sales: 74.81
- Book Value: ($0.01) per share
- Price / Book: -6.18
- Average Volume: 3.70 million shs.
- Beta: -0.28
- Short Ratio: 2.82
Frequently Asked Questions for CEL-SCI (NYSEMKT:CVM)
What is CEL-SCI's stock symbol?
CEL-SCI trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "CVM."
How were CEL-SCI's earnings last quarter?
CEL-SCI Co. (NYSEMKT:CVM) issued its earnings results on Wednesday, May, 10th. The company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $0.02 million for the quarter. View CEL-SCI's Earnings History.
Who are some of CEL-SCI's key competitors?
Some companies that are related to CEL-SCI include Trillium Therapeutics (TRIL), Catasys (CATS), Bio-Path Holdings (BPTH), Nivalis Therapeutics (NVLS), Chiasma (CHMA), Critical Outcome T (COTQF), Electromed (ELMD), EnteroMedics (ETRM), Histogenics Corp (HSGX), Fibrocell Science (FCSC), Biocept (BIOC), Threshold Pharmaceuticals (THLD), Tonix Pharmaceuticals Holding Corp. (TNXP), OmniComm Systems (OMCM), Can Fite Biopharma Ltd (CANF), Soleno Therapeutics (SLNO), Evoke Pharma (EVOK) and Check Cap Ltd (CHEK).
How do I buy CEL-SCI stock?
Shares of CEL-SCI can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of CEL-SCI stock cost?
One share of CEL-SCI stock can currently be purchased for approximately $0.09.
Consensus Ratings for CEL-SCI (NYSEMKT:CVM) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for CEL-SCI (NYSEMKT:CVM)
(Data available from 5/27/2015 forward)
|3/11/2016||Dawson James||Reiterated Rating||Buy|
Earnings History for CEL-SCI (NYSEMKT:CVM)Earnings History by Quarter for CEL-SCI (NYSEMKT:CVM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2017||Q2 2017||($0.05)||$0.02 million||View||N/A|
|5/8/2015||Q2 2015||($0.12)||($0.17)||$0.10 million||$0.20 million||View||N/A|
|2/6/2015||Q1 2015||($0.09)||($0.11)||$0.07 million||$0.14 million||View||N/A|
|5/13/2014||Q114||($0.11)||($0.24)||$0.02 million||$0.07 million||View||N/A|
Earnings Estimates for CEL-SCI (NYSEMKT:CVM)
Current Year EPS Consensus Estimate: $-0.4200 EPS
Next Year EPS Consensus Estimate: $-0.2900 EPS
Dividend History for CEL-SCI (NYSEMKT:CVM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for CEL-SCI (NYSEMKT:CVM)Insider Trades by Quarter for CEL-SCI (NYSEMKT:CVM)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/13/2014||Geert R Kersten||CEO||Buy||14,999||$0.77||$11,549.23|| |
|12/30/2013||Geert R Kersten||CEO||Buy||300,000||$0.60||$180,000.00|| |
|10/9/2013||Geert R Kersten||Insider||Buy||8,400||$0.79||$6,636.00|| |
|6/19/2013||Peter R Young||Director||Buy||25,000||$0.24||$6,000.00|| |
|6/14/2013||Geert R Kersten||Insider||Buy||145,120||$0.24||$34,828.80|| |
|5/20/2013||Geert R Kersten||CEO||Buy||40,000||$0.25||$10,000.00|| |
|5/2/2013||Geert R Kersten||CEO||Buy||118,700||$0.27||$32,049.00|| |
|3/27/2013||Peter R Young||Director||Buy||25,000||$0.23||$5,750.00|| |
|3/26/2013||Geert R Kersten||CEO||Buy||348,125||$0.21||$73,106.25|| |
Headline Trends for CEL-SCI (NYSEMKT:CVM)
Latest Headlines for CEL-SCI (NYSEMKT:CVM)